RxDoctor Payments Data

Meagan Shepherd, MD

Allergy & Immunology · Barboursville, WVNPI 1184815003

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,700 of the $8,277 with a category attached, or 68.9%. Pfizer accounts for 62.6% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $5,000 and has fallen 75.3% since, to $1,237 in 2025.

$8,277in general payments, 2019–2025

Across 100 payments — averaging $82.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$448
  • Novartis$190
  • Takeda Pharmaceuticals U.S.A., Inc.$189
  • Lilly USA, LLC$161
  • plus $842 from 10 others
$33,790in research payments, 2019–2025

Across 27 payments — averaging $1251.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shire North American Group Inc$21K
  • Takeda Pharmaceuticals U.S.A., Inc.$13K

What the payments were for

  • Speaking & faculty fees$5,70069%
  • Food & beverage$2,39229%
  • Education$1852%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$16,469
Medicare patients
45
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymbicortBudesonide/Formoterol Fumarate17$4,211
Epinephrine18$4,102
Azelastine Hcl42$616
Ipratropium Bromide22$523
Albuterol Sulfate HfaAlbuterol Sulfate19$514
Azithromycin16$316
Levocetirizine Dihydrochloride20$169
Famotidine15$43
Prednisone14$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$1,262$4,21117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Barboursville

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →